Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 12/20 | 0.58 |
| ▸ | FCER2 | P06734 | 2/20 | 0.58 |
| ▸ | MMP2 | P08253 | 14/20 | 0.55 |
| ▸ | MMP3 | P08254 | 8/20 | 0.55 |
| ▸ | MMP9 | P14780 | 4/20 | 0.53 |
| ▸ | MMP8 | P22894 | 4/20 | 0.53 |
| ▸ | MMP7 | P09237 | 3/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4428861 | 1.00 | MMP1 (0.58) | MMP1FCER2MMP2MMP3MMP9 | |
| SCHEMBL4428864 | 1.00 | MMP1 (0.58) | MMP1FCER2MMP2MMP3MMP9 | |
| SCHEMBL19361059 | 0.93 | MMP1 (0.64) | MMP1FCER2MMP2MMP3MMP9 | |
| SCHEMBL22962378 | 0.93 | MMP1 (0.64) | MMP1FCER2MMP2MMP3MMP9 | |
| SCHEMBL7439018 | 0.89 | MMP1 (0.58) | MMP1FCER2MMP2MMP3MMP9 | |
| SCHEMBL7439020 | 0.89 | MMP1 (0.58) | MMP1FCER2MMP2MMP3MMP9 | |
| SCHEMBL16254380 | 0.88 | CYP2D6 (0.54) | MMP1FCER2MMP2MMP3 | |
| SCHEMBL21988101 | 0.86 | MMP1 (0.63) | MMP1FCER2MMP2MMP3MMP9 | |
| SCHEMBL7762294 | 0.86 | MMP1 (0.56) | MMP1FCER2MMP2MMP3MMP9 | |
| SCHEMBL7762297 | 0.86 | MMP1 (0.56) | MMP1FCER2MMP2MMP3MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111479819-B | Method for preparing peptide and method for treating alkali | 中外制药株式会社 | 2024-06-14 | — | — | CN | disclosed |
| US-11492369-B2 | Method for producing peptide, and method for processing bases | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2022-11-08 | — | — | US | disclosed |
| WO-2021159021-A1 | LIPID PRODRUGS OF NEUROSTEROIDS | PURETECH LYT, INC. (US) | 2021-08-12 | — | — | WO | disclosed |
| US-20210061860-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2021-03-04 | — | — | US | disclosed |
| US-9409952-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-08-09 | — | — | US | disclosed |
| WO-2010022249-A2 | MACROCYCLIC COMPOUNDS FOR INHIBITION OF TUMOR NECROSIS FACTOR ALPHA | ENSEMBLE DISCOVERY CORPORATION (US) | 2010-02-25 | — | — | WO | disclosed |
| US-20040176393-A1 | Statin-MMP inhibitor combinations | NEWTON ROGER SCHOFIELD (US) | 2004-09-09 | — | — | US | disclosed |
| EP-1063991-A1 | STATIN-MATRIX METALLOPROTEINASE INHIBITOR COMBINATIONS | WARNER-LAMBERT COMPANY LLC (US) | 2001-01-03 | — | — | EP | disclosed |
| EP-1047450-A1 | ACE INHIBITOR-MMP INHIBITOR COMBINATIONS | WARNER-LAMBERT COMPANY (US) | 2000-11-02 | — | — | EP | disclosed |
| EP-0946166-A1 | USE OF MATRIX METALLOPROTEINASE INHIBITORS FOR TREATING NEUROLOGICAL DISORDERS AND PROMOTING WOUND HEALING | WARNER-LAMBERT COMPANY (US) | 1999-10-06 | — | — | EP | disclosed |
| WO-1999047138-A1 | STATIN-MATRIX METALLOPROTEINASE INHIBITOR COMBINATIONS | WARNER-LAMBERT COMPANY (US) | 1999-09-23 | — | — | WO | disclosed |
| WO-1999032150-A1 | ACE INHIBITOR-MMP INHIBITOR COMBINATIONS | WARNER-LAMBERT COMPANY (US) | 1999-07-01 | — | — | WO | disclosed |
| WO-1998026773-A1 | USE OF MATRIX METALLOPROTEINASE INHIBITORS FOR TREATING NEUROLOGICAL DISORDERS AND PROMOTING WOUND HEALING | WARNER-LAMBERT COMPANY (US) | 1998-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176393-A1 | Statin-MMP inhibitor combinations | MMP9, TIMP3, MMP3 | MMP1 20/4885FCER2 4226/4885MMP2 19/4885 |
| US-20210061860-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | VIP, NGLY1, GLP1R | MMP1 2702/4885FCER2 4449/4885MMP2 1620/4885 |
| US-11492369-B2 | Method for producing peptide, and method for processing bases | VIP, NPPA, PTMS | MMP1 3040/4885FCER2 4689/4885MMP2 2019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.